1. Scrip
  2. >>Business
  3. >>Deals

Andera Reflects On Revitalized Biotech Scene

 
• By Kevin Grogan

After AstraZeneca’s acquisition of Amolyt made the Paris-based investment group a tidy profit, Andera spoke to Scrip about the rejuvenated investment market in Europe.

Business growth
• Source: Shutterstock

The partners at Andera Life Sciences have been reflecting on a busy week which saw the France-headquartered private equity firm wave goodbye to portfolio company Amolyt Pharma, sold to AstraZeneca PLC, and increase its investment in Tubulis GmbH, all on the same day.

A very eventful 14 March began with the acquisition of Amolyt by AstraZeneca's rare disease division Alexion for $800m upfront, plus a potential $250m milestone dependent on the approval of the French biotech's eneboparatide, a peptide therapy for hypoparathyroidism that is in Phase III trials. The deal represents a healthy return for Andera which plumped for Amolyt as the first investment in September 2021 for its sixth biodiscovery fund worth €456m and participated in its $138m series C fundraising in early 2023

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.